B. Metzler Seel. Sohn & Co. Ag Catalent, Inc. Transaction History
B. Metzler Seel. Sohn & Co. Ag
- $10 Billion
- Q3 2024
A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Catalent, Inc. stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 4,554 shares of CTLT stock, worth $289,087. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,554
Previous 4,554
-0.0%
Holding current value
$289,087
Previous $256,000
7.42%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CTLT
# of Institutions
514Shares Held
149MCall Options Held
575KPut Options Held
2.03M-
Vanguard Group Inc Valley Forge, PA20.2MShares$1.28 Billion0.02% of portfolio
-
Black Rock Inc. New York, NY15.4MShares$975 Million0.02% of portfolio
-
State Street Corp Boston, MA7.45MShares$473 Million0.02% of portfolio
-
Capital World Investors Los Angeles, CA6.4MShares$406 Million0.06% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.52MShares$287 Million0.14% of portfolio
About Catalent, Inc.
- Ticker CTLT
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 179,896,000
- Market Cap $11.4B
- Description
- Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...